Anatomic Pathology Market to reach US$ 36.5 bn by 2031

According to a new research study by Global Insight Services (GIS), the anatomic pathology market is expected to grow rapidly over the next 10 years to reach a value of more than the US $36.5 billion by 2031.

Anatomical pathology is the branch of medicine that comprises the study of body organs and tissues. Anatomical pathology is considered one of the diagnostic branches of medicine, coupled with radiology and other pathology specialties (such as microbiology and chemical pathology). Its roles comprise determining the cause of certain diseases and the effect that they are having on the body, assisting with the choice of treatment that will be given, aiding in giving a prognosis, and determining what may have caused a person’s death.

Request Sample Pages of this Research Report:

Anatomic Pathology Market: Key Drivers

Rising incidence of cancer and other target diseases

Cancer is a leading cause of death across the globe, which accounts for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancer are breast, lung, colon and rectum, and prostate cancers. Around one-third of cancer deaths are due to tobacco use, high body mass index, alcohol consumption, low fruit and vegetable intake, and lack of physical activity. Like HPV and hepatitis, cancer-causing infections are responsible for approximately 30% of cancer cases in low and lower-middle-income countries. Many cancers can be cured if detected early and treated effectively.

The increasing number of clinical trials pertaining to cancer drugs

Anatomic pathology products and services are used in oncology drug trials to analyze quantitative information as well as to detect morphological structures, detect pharmacodynamic markers, and understand drug mechanisms. It is also used to stratify trial subjects based on the responses given by tissues to the drugs. Tissue diagnostics thus facilitate efficient trials and retrospective studies by reducing the cost and time involved in these processes. For instance, in a Phase III study for Roche’s cancer immunotherapy—TECENTRIQ (atezolizumab)—the PD-L1 (programmed death-ligand 1) expression was evaluated using an investigational immunohistochemistry (IHC) test, which was developed by Roche Tissue Diagnostics.

Report Findings

The services segment is likely to hold a major market share during the forecast period

The key factors boosting market growth are the rising geriatric population coupled with increasing incidences of cancer and other chronic diseases.

The disease diagnostics segment is likely to hold a major market share during the forecast period

The key factors propelling the market growth are the increasing incidence of cancer and other diseases coupled with growing geriatric populations

The hospital laboratories are likely to hold a majority of the market share during the forecast period

The market growth of the segment is attributed to the increasing number of patient visits to hospitals, increasing number of in-house diagnostic procedures performed in hospitals, increasing awareness regarding early disease diagnosis, and the availability of reimbursement in the developed market for clinical tests performed in hospitals.

Competitive Landscape

The key players in the global anatomic pathology market are F. Hoffmann-La Roche AG, Danaher Corporation, PHC Holdings Corporation, Beckton, Dickson and Company, Abcam plc., Hologic, Inc., Agilent Technologies, Merck KGaA, Sakura Finetek, Bio SB, BioGenex, Milestone Medical, Histo-Line Laboratories, Diapath S.p.A, SLEE medical GmbH, Amos Scientific Pty Ltd, MEDITE Medical GmbH, Cell Signaling Technology, Inc., CellPath Ltd., Jinhua Yidi Medical Equipment Co., Ltd., MICROS AUSTRIA, R. K. SCIENTIFIC INSTRUMENT PRIVATE LIMITED, Lupetec, Medimeas, and Bright Instruments among others.